Abstract
Retinoblastoma and uveal melanoma, the two most common primary intraocular malignancies in children and adults, are extremely rare, limiting the ability to perform large-scale clinical trials in humans. Pre-clinical animal models allow the exploration of genetic driver mutations in tumor development and metastasis as well as testing of chemotherapeutics and other treatment modalities. There are three types of pre-clinical animal models including: (1) xenografts, (2) knock-out models, and (3) transgenic models. This chapter will explore the benefits and limitations of existing pre-clinical animal models for retinoblastoma, uveal melanoma, and briefly adenoid cystic carcinoma. Additionally, two pre-clinical animal models exploring the effects of intra-arterial chemotherapy technique and drug choice on the eye are reviewed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Nair RM, Kaliki S, Vemuganti GK. Animal models in retinoblastoma research. Saudi J Ophthalmol. 2013;27(3):141–6.
Cassoux N, Thuleau A, Assayag F, Aerts I, Decaudin D. Establishment of an orthotopic xenograft mice model of retinoblastoma suitable for preclinical testing. Ocul Oncol Pathol. 2015;1(3):200–6.
Tschulakow AV, Schraermeyer U, Rodemann HP, Julien-Schraermeyer S. Establishment of a novel retinoblastoma (Rb) nude mouse model by intravitreal injection of human Rb Y79 cells - comparison of in vivo analysis versus histological follow up. Biol Open. 2016;5(11):1625–30.
Broaddus E, Topham A, Singh AD. Incidence of retinoblastoma in the USA: 1975-2004. Br J Ophthalmol. 2009;93(1):21–3.
Daniels AB, Froehler MT, Pierce JM, Nunnally AH, Calcutt MW, Bridges TM, et al. Pharmacokinetics, tissue localization, toxicity, and treatment efficacy in the first small animal (rabbit) model of intra-arterial chemotherapy for retinoblastoma. Invest Ophthalmol Vis Sci. 2018;59(1):446–54.
Richards JR, Yoo JH, Shin D, Odelberg SJ. Mouse models of uveal melanoma: strengths, weaknesses, and future directions. Pigment Cell Melanoma Res. 2020;33(2):264–78.
McLaughlin CC, Wu XC, Jemal A, Martin HJ, Roche LM, Chen VW. Incidence of noncutaneous melanomas in the U.S. Cancer. 2005;103(5):1000–7.
Damato EM, Damato BE. Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2,384 patients. Ophthalmology. 2012;119(8):1582–9.
Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118(9):1881–5.
Mills MD, Windle JJ, Albert DM. Retinoblastoma in transgenic mice: models of hereditary retinoblastoma. Surv Ophthalmol. 1999;43(6):508–18.
Nair RM, Vemuganti GK. Transgenic models in retinoblastoma research. Ocul Oncol Pathol. 2015;1(3):207–13.
Landreville S, Ma D, Wu J, Harbour JW. Loss of Id2 potentiates the tumorigenic effect of Rb inactivation in a mouse model of retinoblastoma. Curr Eye Res. 2010;35(5):435–9.
MacPherson D, Dyer MA. Retinoblastoma: from the two-hit hypothesis to targeted chemotherapy. Cancer Res. 2007;67(16):7547–50.
Naert T, Colpaert R, Van Nieuwenhuysen T, Dimitrakopoulou D, Leoen J, Haustraete J, et al. CRISPR/Cas9 mediated knockout of rb1 and rbl1 leads to rapid and penetrant retinoblastoma development in Xenopus tropicalis. Sci Rep. 2016;6:35264.
Carita G, Nemati F, Decaudin D. Uveal melanoma patient-derived xenografts. Ocul Oncol Pathol. 2015;1(3):161–9.
Reid TW, Albert DM, Rabson AS, Russell P, Craft J, Chu EW, et al. Characteristics of an established cell line of retinoblastoma. J Natl Cancer Inst. 1974;53(2):347–60.
McFall RC, Sery TW, Makadon M. Characterization of a new continuous cell line derived from a human retinoblastoma. Cancer Res. 1977;37(4):1003–10.
Chevez-Barrios P, Hurwitz MY, Louie K, Marcus KT, Holcombe VN, Schafer P, et al. Metastatic and nonmetastatic models of retinoblastoma. Am J Pathol. 2000;157(4):1405–12.
Lemaitre S, Poyer F, Marco S, Freneaux P, Doz F, Aerts I, et al. Looking for the most suitable orthotopic retinoblastoma mouse model in order to characterize the tumoral development. Invest Ophthalmol Vis Sci. 2017;58(7):3055–64.
Kang SJ, Grossniklaus HE. Rabbit model of retinoblastoma. J Biomed Biotechnol. 2011;2011:394730.
Jo DH, Son D, Na Y, Jang M, Choi JH, Kim JH, et al. Orthotopic transplantation of retinoblastoma cells into vitreous cavity of zebrafish for screening of anticancer drugs. Mol Cancer. 2013;12:71.
Cao J, Jager MJ. Animal eye models for uveal melanoma. Ocul Oncol Pathol. 2015;1(3):141–50.
Lin T, Zhu L, Zhou B, Xie L, Lv J, Dong L, et al. Establishment and characterization of a cell line from human adenoid cystic carcinoma of the lacrimal glands and a nude mouse transplantable model. Oncol Rep. 2015;33(6):2797–806.
Ditta LC, Choudhri AF, Tse BC, Landers MM, Haik BG, Steinle JJ, et al. Validating a nonhuman primate model of super-selective intraophthalmic artery chemotherapy: comparing ophthalmic artery diameters. Invest Ophthalmol Vis Sci. 2012;53(12):7791–4.
Tse BC, Steinle JJ, Johnson D, Haik BG, Wilson MW. Superselective intraophthalmic artery chemotherapy in a nonhuman primate model: histopathologic findings. JAMA Ophthalmol. 2013;131(7):903–11.
Wilson MW, Jackson JS, Phillips BX, Buchanan J, Frase S, Wang F, et al. Real-time ophthalmoscopic findings of superselective intraophthalmic artery chemotherapy in a nonhuman primate model. Arch Ophthalmol. 2011;129(11):1458–65.
Daniels AB, Froehler MT, Nunnally AH, Pierce JM, Bozic I, Stone CA, et al. Rabbit model of intra-arterial chemotherapy toxicity demonstrates retinopathy and vasculopathy related to drug and dose, not procedure or approach. Invest Ophthalmol Vis Sci. 2019;60(4):954–64.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Kornblau, I.S., Brennan, R.C., Wilson, M.W. (2022). Developing Animal Models in Ocular Oncology. In: Chawla, B.V., Aronow, M.E. (eds) Global Perspectives in Ocular Oncology. Springer, Cham. https://doi.org/10.1007/978-3-031-08250-4_26
Download citation
DOI: https://doi.org/10.1007/978-3-031-08250-4_26
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-08249-8
Online ISBN: 978-3-031-08250-4
eBook Packages: MedicineMedicine (R0)